The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
about
Haloperidol versus placebo for schizophreniaHaloperidol versus placebo for schizophreniaProfile of blonanserin for the treatment of schizophreniaBlonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC.Moving psychopharmacological drug development to the developing world.Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation.Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake.Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophreniaTargeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Blonanserin - A Novel Antianxiety and Antidepressant Drug? An Experimental Study.Rater evaluations for psychiatric instruments and cultural differences: the positive and negative syndrome scale in China and the United States.Dose equivalents for second-generation antipsychotics: the minimum effective dose method.Emerging drugs for schizophrenia.Newer antipsychotics and upcoming molecules for schizophrenia.Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management.Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities.Loxapine to control agitation during weaning from mechanical ventilation.Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases.Simple and sensitive analysis of blonanserin and blonanserin C in human plasma by liquid chromatography tandem mass spectrometry and its application.Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study.Early prediction of blonanserin response in Japanese patients with schizophrenia.Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT(2A) activity/anti-dopamine D₂ activity ratio and drug-induced extrapyramidal symptoms.Psychotic mania as the solitary manifestation of neurosyphilis.
P2860
Q24202457-CE2DE66D-179F-4D4F-AD12-98478467A130Q24243823-5B370F15-F612-43B3-B5B1-37009DDA975EQ24614169-874764DB-C6E6-4E7A-85CF-AFCC321DA55DQ27311205-D01F6E49-2E6C-44F5-B10D-DB4E7422967CQ33692055-F5E78100-170C-4DB1-BFBA-6F87748227BFQ34026829-4E9C74D5-4CA8-4153-9E08-118366F974ABQ34328266-A3493084-619D-4F82-8372-0CE2994CB031Q35007214-10E5679D-7D09-4764-AFA2-8BEC47D975E3Q35071909-7A8C97CC-8FD5-4E1D-8143-340FEBC588EFQ35088447-044A9F49-1068-4F57-BDB8-7AF3E952E2A7Q37352996-2EA5BEE1-5A66-484E-91DC-99227BB437FDQ37450905-7E416E20-5717-4AAB-B0E6-D83DCD033FB1Q37598284-E764504D-F1A4-4794-A147-57C8201FE9A8Q37874626-FD59D836-6E07-4FB6-ABFD-B245468E09F4Q38094930-F5C5F843-5692-4B86-9170-AD1B38BA70A3Q38884279-2F45F743-B823-49F2-8894-187F6FFA11C1Q39346287-75E90E01-CFB5-4635-AA56-BEE0FA9CE6F1Q40064143-64008530-2F65-44EA-9DA1-FE125A909459Q40489548-6E1918A9-B4E4-4076-8871-D2C464C1F5FFQ41997913-B288F5F3-66A9-4773-838F-666EF0C1168AQ42395373-1A798A4F-C27D-4D23-A8B3-546F7E54236EQ42924056-3B97793B-4FA7-4AD8-85C6-1EF7CE576AB3Q48076232-D0DF4CA3-7117-4531-9EAF-9C90986EF3F9Q50516552-B237B0EF-F444-4EFA-9794-A23635C6567EQ55205969-DAFA7133-B63F-4062-8375-F767992887B8
P2860
The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The efficacy and safety of blo ...... controlled, multicentre study.
@ast
The efficacy and safety of blo ...... controlled, multicentre study.
@en
The efficacy and safety of blo ...... controlled, multicentre study.
@nl
type
label
The efficacy and safety of blo ...... controlled, multicentre study.
@ast
The efficacy and safety of blo ...... controlled, multicentre study.
@en
The efficacy and safety of blo ...... controlled, multicentre study.
@nl
prefLabel
The efficacy and safety of blo ...... controlled, multicentre study.
@ast
The efficacy and safety of blo ...... controlled, multicentre study.
@en
The efficacy and safety of blo ...... controlled, multicentre study.
@nl
P2093
P921
P1433
P1476
The efficacy and safety of blo ...... controlled, multicentre study.
@en
P2093
Esther Garcia
Francesc Peris
Hiroshi Nakamura
Marta Robert
Noriko Sato
Yoshikatsu Terazawa
P304
P356
10.2165/00023210-200923070-00006
P577
2009-01-01T00:00:00Z
P6179
1041303433